<DOC>
	<DOCNO>NCT00503451</DOCNO>
	<brief_summary>The primary purpose open-label study investigate interaction ketoconazole , liver enzyme inhibitor , oral LBH589 adult patient advance solid tumor . The extension phase study evaluate safety efficacy LBH589 patient advance solid tumor .</brief_summary>
	<brief_title>A Study Investigate Effects Ketoconazole LBH589 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Inclusion criterion : Patients histologically confirm solid tumor nonHodgkin 's lymphoma progression prior standard therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Adequate kidney function laboratory value Exclusion criterion : Patients receive chemotherapy , investigational drug , undergone major surgery , receive wide field radiotherapy le 4 week ago Patients heart attack unstable angina within past 6 month Heart disease include congestive heart failure uncontrolled high blood pressure Liver disease , abnormal gastrointestinal ( GI ) function ongoing diarrhea Use anticancer therapy , include radiation therapy , certain drug study Female patient pregnant breast feeding . Other protocol inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>HDAC</keyword>
	<keyword>LBH589</keyword>
	<keyword>adult</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
</DOC>